【レポートの概要（一部）】
1. Report Overview
1.1 Next-Generation Antibody Therapies Overview
1.2 Global Next-Generation Antibody Therapies Market Segmentation
1.3 Why you Should Read this Report
1.4 How this Report Delivers
1.5 Main Questions Answered by This Analytical Study
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain
2. Introduction to Next-Generation Antibody Therapies
2.1 Antibodies: An Overview
2.1.1 Monoclonal versus Polyclonal Antibodies
2.1.2 A Brief History of Antibody Drug Development
2.1.3 The Antibody Manufacturing Process
2.1.4 Trends in Antibody Development
2.2 Defining Next-Generation Antibodies
2.3 Classification of Next-Generation Antibody Therapies
2.4 The Need for Next-Generation Technologies
2.5 Development Trends for Next-Generation Antibodies
2.6 Scope of this Report
2.7 Phases of Clinical Trials
3. Next-Generation Antibody Therapies: World Market 2016-2026
3.1 The World Next-Generation Antibody Therapies Market Overview and Segmentation, 2015
3.2 Leading Next-Generation Antibody Therapies
3.3 World Next-Generation Antibody Therapies Market: Sales Forecast 2016-2026
3.4 How Will Segmental Market Shares Change to 2026?
3.4 World Next-Generation Antibody Therapies Market: Drivers and Restraints 2016-2026
4. Leading Regional Markets 2016-2026
4.1 Regional Breakdown of the World Next-Generation Antibody Therapies Market, 2015
4.2 World Next-Generation Antibody Therapies Market: Regional Forecast 2016-2026
4.3 How Will Regional Market Shares Change to 2026?
4.4 US Next-Generation Antibody Therapies Market 2015-2026
4.5 EU5 Next-Generation Antibody Therapies Market 2016-2026
4.6 Asia-Pacific Next-Generation Antibody Therapies Market 2016-2026
4.7 Latin American Next-Generation Antibody Therapies Market 2016-2026
4.8 The Next-Generation Antibody Therapies Market in the Rest of the World 2016-2026
5. Antibody-Drug Conjugates: Market Forecast and Pipeline 2016-2026
5.1 Market Overview, 2016
5.2 Leading ADCs in 2016
5.3 Antibody-Drug Conjugates: Market Forecast 2016-2026
5.4 The Antibody-Drug Conjugates Market: Drivers and Restraints 2016-2026
5.4.1 Competition for Leading Drugs Will Restrain Growth
5.4.2 Manufacturing ADCs Forms a Challenge
5.5 Adcetris (brentuximab vedotin, Seattle Genetics / Takeda)
5.5.1 Adcetris: Sales 2011-2015
5.5.2 Adcetris Results in AETHERA Trial and Approval for in HL following Stem Cell Transplantation
5.5.3 Expanding Adcetris Indications for Future Revenue Growth
5.5.4 Adcetris Sales Forecast 2016-2026
5.6 Kadcyla (trastuzumab emtansine, Roche)
5.6.1 Mixed Results from Different Clinical Trials
5.6.2 NICE Rejects Kadcyla on Cost Grounds, but it Just Manages to Hold on in the Cancer Drugs Fund List
5.6.3 Kadcyla Sales Forecast 2016-2026
5.7 Mylotarg (gemtuzumab ozogamicin, Pfizer)
5.7.1 Mylotarg to be Relaunched?
5.8 Antibody-Drug Conjugate Platforms
5.8.1 Limited Market Opportunity for Radioconjugation
5.8.2 Seattle Genetics’ Platform Accounted for Over 50% of the Pipeline in 2015
5.8.3 ImmunoGen: TAP Technology
5.8.4 Immunomedics: Lower Potency Cytotoxics for Extended Use
5.8.5 Preclinical Platforms for ADC Development
5.9 ADCs Have Attracted High-Value Deals and will Continue to do so
5.10 Antibody-Drug Conjugates: Pipeline Analysis 2015-2026
5.10.1 The Longest Pipeline in the Next-Generation Antibodies Market
5.10.2 Cancer Is the Only Target for Current Clinical-Stage ADCs
5.11 Antibody-Drug Conjugates: Phase 3 Pipeline
5.11.1 CMC544 (inotuzumab ozogamicin, Pfizer)
5.11.1.1 Granted Breakthrough Therapy Designation
5.11.2 Roche Attempting to Expand Kadcyla Indications and also Possesses some Unique ADCs in the Pipeline
5.11.2.1 RG7596 (polatuzumab vedotin) for NHL and DLBCL
5.11.2.2 RG7599/DNIB0600A (anti-NaPi2b) for Ovarian Cancer
5.11.2.3 RG7450/DSTP3086S (anti-STEAP1) for Prostate Cancer
5.12 Antibody-Drug Conjugates: Phase 2 Pipeline
5.12.1 ABT-414 (anti-EGFR, AbbVie/Seattle Genetics)
5.12.2 BT-062 (indatuximab ravtansine; anti-CD138, Biotest)
5.12.3 CDX-011 (glembatumumab vedotin; anti-glycoprotein NMB, Celldex Therapeutics/Seattle Genetics)
5.12.4 Immunomedics’ IMMU-130 (labetuzumab-SN-38; anti-CEA/CD66e) and IMMU-132 (anti-TROP-2)
5.12.5 MLN0264 (anti-GCC, Millennium Pharmaceuticals/Seattle Genetics)
5.12.6 MM-302 (anti-HER2, Merrimack Pharmaceuticals)
5.12.7 PSMA ADC (anti-PSMA, Progenics Pharmaceuticals/Seattle Genetics)
5.12.8 SAR3419 (coltuximab ravtansine) (anti-CD19, Sanofi)
5.12.9 Seattle Genetics’ Phase 1 and Phase 2 ADCs
5.12.9.1 SGN-CD19A (anti-CD19) for DLBCL and ALL
5.12.9.2 SGN-LIV1A (anti-LIV-1) for Relapsed Breast Cancer
5.12.9.3 SGN-CD33A: Using a New Cytotoxin and Linker Technology
5.12.9.4 SGN-CD70A (anti-CD70, Seattle Genetics)
5.13 Antibody-Drug Conjugates: Phase 1 Pipeline
5.14 Antibody-Drug Conjugates: Preclinical Pipeline
5.15 Future Developments in ADC Technology
5.15.1 Site-Specific Linkage for Improved Safety Profiles
6. Engineered Antibodies: Market Forecast and Pipeline 2016-2026
6.1 Defining an ‘Engineered Antibody’
6.2 Market Overview 2016, and the Leading Engineered Antibodies
6.3 Leading Engineered Antibodies: Market Forecast 2016-2026
6.4 The Engineered Antibodies Market: Drivers and Restraints 2015-2026
6.5 Poteligeo (mogamulizumab, Kyowa Hakko Kirin)
6.5.1 Poteligeo Sales Forecast 2016-2026
6.6 Gazyva / Gazyvaro (obinutuzumab, Roche)
6.6.1 Gazyva as a Challenger in the anti-CD20 Market
6.6.2 Competition beyond Rituxan and Biosimilars
6.6.3 Gazyva Receives Second Approval
6.6.4 Gazyva Sales Forecast 2016-2026
6.7 Engineered Antibodies Platforms
6.7.1 Roche Glycart: GlucoMAb – Glycosylation for Improved ADCC
6.7.2 Kyowa Hakko Kirin: Potelligent – Enhancing ADCC
6.7.3 Glycotope: GlycoExpress
6.7.4 MacroGenics: Fc Optimization
6.7.5 Xencor: XmAb – Modifying Amino Acids in the Fc Domain
6.7.6 Other Platforms for Increased Potency
6.8 Engineered Antibodies: Pipeline Analysis 2016-2026
6.9 Engineered Antibodies: Phase 3 Pipeline
6.9.1 Benralizumab (MedImmune / Kyowa Hakko Kirin)
6.9.2 Elotuzumab (anti-SLAMF7, Bristol-Myers Squibb/AbbVie)
6.9.3 MEDI4736 (anti-PDL1, AstraZeneca)
6.9.4 RG7446/MPDL3280A (anti-PDL1, Roche)
6.9.5 Ublituximab (anti-CD20, TG Therapeutics)
6.10 Engineered Antibodies: Phase 2 Pipeline
6.10.1 Glycotope’s CetuGEX (anti-EGFR), PankoMab-GEX (anti-TA-MUC1) and TrasGEX (anti-HER2)
6.10.2 Margetuximab (anti-HER2, MacroGenics)
6.10.3 MEDI-551 (anti-CD19, AstraZeneca)
6.10.4 MOR-208 (XmAb5574) (anti-CD19, MorphoSys/Xencor)
6.10.5 Teplizumab (anti-CD3, MacroGenics)
6.10.6 BIW-8962 (anti-GM2, Kyowa Hakko Kirin)
6.10.7 XmAb5871 (anti-CD19, Xencor)
6.11 Engineered Antibodies: Phase 1 Pipeline
7. Bispecific Antibodies: Market Forecast and Pipeline 2016-2026
7.1 Bispecific Antibodies: Market Overview, 2016
7.2 Bispecific Antibodies: Market Forecast 2016-2026
7.3 The Bispecific Antibodies Market: Drivers and Restraints 2016-2026
7.4 Removab (catumaxomab, Neopharm)
7.4.1 Removab: Sales Forecast 2016-2026
7.5 Blincyto (blinatumomab, Amgen)
7.5.1 Amgen Files a Supplemental Biologics License Application, and the EU approves Blincyto
7.5.2 Blincyto: Sales Forecast 2016-2026
7.6 Bispecific Antibodies Platforms
7.6.1 BiTE Platform: The Current Market Leader
7.6.2 MacroGenics’ DART Platform Holds Promise
7.6.3 TriomAbs (TRION Pharma): Limited Market Impact 2016-2026
7.6.4 Other Bispecific Antibody Platforms
7.6.4.1 DuoBodies (Genmab)
7.6.4.2 ImmTAC (Immunocore)
7.7 Bispecific Antibodies: Pipeline Analysis 2015-2026
7.7.1 Bispecific Antibodies: Phase 2 and Phase 3 Pipeline
7.7.2 ABT-122 (anti-TNF and IL-17A) and ABT-981 (anti-IL-1α and IL-1β, AbbVie)
7.7.3 AFM13 (anti-CD30 and CD16A, Affimed Therapeutics)
7.7.4 MM-111 (anti-ErbB2 and ErbB3, Merrimack Pharmaceuticals)
7.7.5 MM-141 (anti-IGF-1R and ErbB3, Merrimack Pharmaceuticals)
7.7.6 SAR156597 (anti-IL-4 and IL-13, Sanofi)
7.7.7 Vanucizumab (RG7221; anti-Ang2 and VEGF-A, Roche)
7.8 Bispecific Antibodies: Phase 1, Phase 1/2 and Preclinical Pipeline
8. Antibody Fragments and Antibody-Like Proteins (ALPs): Market Forecast and Pipeline 2016-2026
8.1 Antibody Fragments and ALPs: Market Overview, 2016
8.2 Antibody Fragments and ALPs: Market Forecast 2015-2026
8.3 The Antibody Fragments and ALPs Market: Drivers and Restraints 2016-2026
8.4 Kalbitor (ecallantide, Shire): Shire Completes Acquisition of Dyax and adds Kalbitor to Portfolio
8.4.1 Kalbitor: Sales Forecast 2016-2026
8.5 Antibody Fragments and ALPs Platforms
8.5.1 Single-chain Variable Fragment Platforms
8.5.1.1 ESBATech and Delenex Therapeutics: Two Approaches Using the Same Platform
8.5.1.2 Nanobodies: The Smallest Antibody Fragment
8.5.1.3 Ablynx’s Nanobody Platform Has Created Many Clinical Candidates
8.5.1.4 Domain Antibodies: GSK and Crescendo Biologics
8.5.2 Non-Antibody Protein Scaffolds: Antibody-Like Proteins
8.5.2.1 DARPins: One-Tenth the Size of Antibodies
8.5.2.2 Anticalins (Pieris): Tested in Clinical Trials
8.5.2.3 Affibodies (Affibody)
8.5.2.4 Fynomers (Covagen/Johnson & Johnson)
8.5.2.5 Affilins (Scil Proteins): Three Products in Pre-Clinical Development?
8.5.2.6 Adnectins (Bristol-Myers Squibb)
8.5.2.7 AdAlta: i-bodies
8.5.3 Which Platform Will Lead the Market 2016-2026?
8.6 Antibody Fragments and ALPs: Pipeline Analysis 2016-2026
8.6.1 Ablynx Leads the Pipeline with Six Clinical Projects
8.7 Antibody Fragments and ALPs: Phase 3 Pipeline
8.7.1 Caplacizumab (anti-vWF, Ablynx)
8.7.2 Abicipar (anti-VEGF, Allergan/Molecular Partners)
8.8 Antibody Fragments and ALPs: Phase 2 Pipeline
8.8.1 ALX-0061 (anti-IL-6R, Ablynx/AbbVie)
8.8.2 Ozoralizumab (anti-TNFα, Ablynx )
8.8.3 DLX105 (anti-TNF-α, Delenex Therapeutics)
8.8.4 ESBA1008 (anti-VEGF, Novartis)
8.9 Antibody Fragments and ALPs: Phase 1 Pipeline
8.9.1 ALX-0761 (anti-IL-17A and IL-17F, Ablynx/Merck Serono)
8.9.2 ALX-0171 (anti-respiratory syncytial virus)
8.9.3 ALX-0141 (anti-RANKL, Ablynx/Eddingpharm)
8.9.4 Other Phase 1 Candidates, and the Preclinical Pipeline
9. Biosimilar Antibodies: Market Forecast 2016-2026
9.1 Biosimilar Antibodies: Market Overview, 2016
9.2 Leading Biosimilar Antibodies in 2016.
9.3 Biosimilar Antibodies: Market Forecast 2016-2026
9.4 The Biosimilar Antibodies Market: Drivers and Restraints 2016-2026
9.4.1 New Launches of Biosimilar mAbs in Developed and Emerging Markets
9.4.2 Rising Incidence of Cancer will Drive Demand
9.4.3 Novel mAb Developers Choosing to Develop Biobetters and Next-Generation Therapies in Face of Biosimilar Competition
9.4.4 Will Biosimilars Challenge Next-Generation Antibodies in this Decade?
10. Qualitative Analysis of the Next-Generation Antibody Therapies Market 2016-2026
10.1 SWOT Analysis of the Next-Generation Antibody Therapies Market
10.1.1 Strengths: The Path Towards Market Acceptance
10.1.2 Weaknesses
10.1.2.1 Challenges Exist With Current Monoclonal Antibody Therapies
10.1.3 Opportunities
10.1.3.1 Big Pharma Is Investing Heavily in Next-Generation Pipelines
10.1.4 Threats
10.1.4.1 Will Biosimilars Slow Growth in the Next-Generation Antibody Market?
10.2 STEP Analysis of the Next-Generation Antibody Therapies Market
10.2.1 Social Factors: Rising Demand for Cancer Therapies
10.2.1.1 Cancer Incidence Is Rising Rapidly
10.2.1.2 Next-Generation Antibodies for Personalised Medicine
10.2.2 Technological Developments Will Drive Pipeline Growth
10.2.2.1 There Are Many Competing Platforms
10.2.2.2 Manufacturing Challenges Exist for Most Sectors
10.2.2.3 New Analytical Tools for Target Identification and Protein Characterisation
10.2.3 Economic Pressures
10.2.3.1 Next-Generation Antibodies Are High-Cost
10.2.3.2 Outsourced Manufacturing: CMOs Are Expanding Capabilities
10.2.3.3 Next-Generation Launches for Product Lifecycle Management
10.2.4 Political and Regulatory Issues
10.2.4.1 Regulatory Challenges for Biosimilar Antibodies
10.3 Key Targets for Next-Generation Antibody Development 2016-2026
10.3.1 Oncology Is the Lead Indication in All Sectors
10.3.1.1 HER2 and HER3 for Breast Cancer
10.3.1.2 CD19 and CD20 for Lymphoma and Leukaemia
11. Research Interviews
11.1 Interview with Dr Edwin Moses, CEO, Ablynx, Belgium
11.1.1 The Benefits of Nanobodies over Traditional Antibody Therapies
11.1.2 Manufacturing Nanobodies
11.1.3 Turning Challenges to Advantages
11.1.4 Nanobodies Are Further Developed than Other Antibody Scaffolds
11.1.5 The Commercial Potential for Nanobodies
11.1.6 Next-Generation Antibodies in China and Other Emerging Markets
11.2 Interview with Tim van Hauwermeiren, CEO, arGEN-X, the Netherlands and Belgium
11.2.1 arGEN-X’s Development Pipeline
11.2.2 Enhancing the Activity of ARGX-111
11.2.3 arGEN-X’s SIMPLE Antibody™ Platform
11.2.4 Commercial Prospects for arGEN-X’s Antibodies
11.2.5 Plans for Growth
11.2.6 Opportunities and Challenges for Next-Generation Antibody Developers
11.2.7 Therapeutic Areas for Manufacturers of Antibody Therapies
11.2.8 Other Trends and Developments in the Market
11.3 Interview with Mersana Therapeutics, Cambridge, Massachusetts, USA
11.3.1 Mersana’s Development Pipeline
11.3.2 Advantages of the Fleximer Platform
11.3.3 Future Plans for Mersana
11.3.4 The Outlook for ADCs in 2015-2026
12. Conclusions
12.1 High Growth Potential in the Next-Generation Antibody Therapies Market in 2015-2026
12.2 Current Status of the Market and Leading Segments
12.3 Leading Next-Generation Antibody Therapies Profiled in this Report
12.4 Leading Regional Markets
12.5 Development of the Market to 2026
12.6 Technology Platforms Will Continue to Attract Big Pharma Interest
12.7 Most Developers Continue to Target Cancer
12.8 Strategies for Growth in 2016-2026
【レポート販売概要】
■ タイトル：次世代抗体治療の世界市場予測2016-2026■ 英文：Next-Generation Antibody Therapies Market Forecast 2016-2026
■ 発行日：2016年4月
■ 調査会社：visiongain
■ 商品コード：VGAIN60630
■ 調査対象地域：グローバル
- 通信キャリアWiFiの世界市場As smartphones and tablets have become increasingly ubiquitous, the increasing mobility advantage offered by these devices means that consumers have come to expect a high standard of network connectivity at all times. Consequently, global data traffic increased from 820 petabytes/month in 2012 to 1.5 exabytes/month in 2013 and 2.8 exabytes/month in 2014. In 2015, visiongain expects the average glo …
- ABB Pioneers Innovation Excellence to Flash-Charge Electric Bus in Fifteen SecondsABB Pioneers Innovation Excellence to Flash-Charge Electric Bus in Fifteen Seconds Summary ABB, a leading power and automation technology company, has developed a new flash-charging system that will power the world’s first flash-charging electric bus system, which can carry 135 passengers. It will provide a 15-second charging boost at selected stops. Benefits include reduced emissions and noise po …
- セラミックフィルターの世界市場：用途別（産業（バイオフィルター、高温ガスフィルター）、住宅、商業施設）、製品別（水フィルター、エアフィルター）、セグメント予測The global ceramic filter market size is expected to reach USD 2.97 billion by 2025, according to a new report by Grand View Research, Inc., progressing at a CAGR of 13.5% during the forecast period. Favorable environmental regulations concerning water treatment, water disposal, and hazardous gas emissions from industrial installations are poised to fuel the demand for the product. Ceramic filters …
- 業務用ガスフライヤーの世界市場2017-2021ABSTRACTAbout Commercial Gas Fryer A commercial gas fryer is a kitchen appliance used for deep frying with the help of heat sources such as natural gas and propane gas. These come in two forms: countertop and floor standing models. The market is primarily driven by the increasing number of foodservice establishments providing fried food items, which largely include breaded poultry and fish items, …
- 心臓麻痺：グローバル臨床試験レビューH1, 2014Cardiac Arrest Global Clinical Trials Review, H1, 2014 Summary GlobalData's clinical trial report, “Cardiac Arrest Global Clinical Trials Review, H1, 2014" provides data on the Cardiac Arrest clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Cardiac Arrest. It includes an overview of the trial numbers and their recruitment status as per …
- 世界のディザスタリカバリサービス（Disaster Recovery-as-a-Service）市場動向（2014-2018）TechNavio's analysts forecast the Global Disaster Recovery-as-a-Service market to grow at a CAGR of 54.64 percent over the period 2014-2018. One of the key factors contributing to this market growth is the increasing need for flexibility of cloud-based disaster recovery services. The Global Disaster Recovery-as-a-Service market has also been witnessing the demand for hybrid cloud disaster recovery …
- 低温装置の世界市場予測（～2021年）：タンク、バルブ、蒸発器、ポンプThe cryogenic equipment market is projected to grow at a CAGR of 6.74% from 2016 to 2021 to reach USD 22.42 Billion by 2021. Increasing demand for LNG and improving healthcare services, especially in the developing economies are the major factors driving the market. The report segments the cryogenic equipment market on the basis of cryogen type into nitrogen, oxygen, argon, LNG, and other cryogens …
- 軍事衛星の世界市場2016-2020About the Military Satellite MarketMilitary satellites are used for conventional missions such as intelligence gathering, navigation, and military communications. These are computer-controlled systems that perform thermal control, telemetry, power generation, attitude control, and orbit control. These data are used for several applications such as agriculture, water resources, urban development, m …
- アジア太平洋のモバイルホットスポットルーター市場About mobile hotspot router A mobile hotspot is a compact wireless router that enables end-users to avail high-speed Internet services without any wires as the device is connected via 3G or 4G mobile connections. It provides connectivity within a range of 30-33 feet and lets users connect multiple Wi-Fi-enabled devices to a single router, thus reducing the overall cost of Internet services for end …
- レベル3自動運転車の世界市場2017-2021About Level 3 Autonomous Vehicles An autonomous vehicle is a vehicle that is able to navigate and drive without any human intervention. This vehicle is equipped with an array of on-board sensors like LiDAR (light detection and ranging), radar, high resolution camera, sonars, laser scanners, and three dimensional (3D) cameras among others to gather and process information about its surroundings and …
- 2014年戦略提言：ヨーロッパの微生物検査市場Complete report $19,700. DataPack (test volumes, sales forecasts, supplier shares) $12,800.“2014 Strategies for the Microbiology Testing Market in Europe” is a new five-country strategic analysis of major business opportunities emerging in the infectious disease testing market during the next five years. The report examines key trends in major European countries ( …
- 飲料容器の世界市場：硬質プラスチック容器、ガラス容器、金属容器About Beverage Containers Owing to their inherent property of rendering product support, external environment protection, and tampering resistance to beverages, the demand for beverage containers is expected to soar in the future. Beverage containers aid in reducing considerably any post production damage. The different types of materials used in the beverage container industry are glass, rigid pl …
- ゼラチンの世界市場2017-2021About Gelatin Gelatin is a colorless, flavorless, semi-transparent, and brittle collagen product. It is a protein food product generally derived from the several animal sources. It is used in several applications as a stabilizer, thickener, and gelling agent. Gelatin is normally graded into categories as per its quality and strength, and the unit is named as 'bloom.' A greater bloom number signifi …
- 産業用ドローン（無人機）の世界市場2016-2020About Commercial-purpose Drones Drones are UAVs. Their flight is controlled with a handheld remote or GPS remote. GPS is used to track the drones. The gyrometer and accelerometer, which are attached to the drones, are used to control the drones during flight. Drones are primarily used for tasks that are of high risk to human life. They are extensively used for surveillance and rescue, emergency re …
- Canacol Energy Ltd：石油・ガスの開発・生産動向及びコスト分析– 2012Canacol Energy Ltd Oil & Gas Exploration and Production Operations and Cost Analysis – 2012 Summary Canacol Energy Ltd Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential source for key o …
